Myeloma MRD by Flowcytometry Test: Booking, Price, and Results
About Myeloma MRD by Flowcytometry Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | MM MRD Flow Cytometry Test, Multiple Myeloma Minimal Residual Disease Test, MRD Myeloma Panel, Measurable Residual Disease Test for Myeloma |
| Sample Type | Bone marrow aspirate and peripheral blood |
| Fasting Required | No fasting required |
| Report Time | 3 days |
| Recommended For | Adults of any gender with a prior diagnosis of multiple myeloma who have undergone treatment |
| Price | Starting at ₹12,000 |
What Is a Myeloma MRD by Flowcytometry Test?
The myeloma MRD by flowcytometry test is a specialised laboratory test used to detect whether any cancerous plasma cells remain in the bone marrow after treatment for multiple myeloma. MRD stands for Measurable Residual Disease, and the test uses a technology called flow cytometry to identify even tiny numbers of abnormal cells. Doctors order this test to confirm whether a patient has achieved remission or to monitor disease status over time. It is also known as the MM MRD flow cytometry test, multiple myeloma minimal residual disease test, MRD Myeloma Panel, or measurable residual disease test for myeloma. This test requires a bone marrow and a peripheral blood sample for analysis.
What Does a Myeloma MRD by Flowcytometry Test Measure?
The myeloma MRD by flowcytometry test analyses bone marrow and peripheral blood samples for a single, specific finding. The table below explains what the test looks for:
| Parameter | What It Detects |
|---|---|
| Measurable Residual Disease (MRD) Status | The presence or absence of abnormal plasma cells (cancerous cells) remaining in the bone marrow after treatment. |
Why Is a Myeloma MRD by Flowcytometry Test Done?
Doctors order this test after a patient with multiple myeloma has completed a course of treatment. It helps confirm the depth of the response and guides decisions about ongoing care.
Common Symptoms That May Require This Test
This test is not ordered based on symptoms alone. It is ordered for patients already diagnosed with multiple myeloma. The following are symptoms associated with the underlying condition that may prompt initial investigation or continued monitoring:
- Bone pain, particularly in the back, chest, pelvis, or upper legs
- Persistent fatigue and weakness, often linked to low red blood cell counts (anaemia)
- Frequent infections caused by reduced white blood cell levels
- Shortness of breath during routine activity
- Dizziness or light-headedness
- Unexplained weight loss
Conditions This Test Can Help Detect
Doctors use the myeloma MRD by flowcytometry test for several specific clinical situations:
- Confirming that remission has been achieved after treatment for multiple myeloma
- Annual follow-up monitoring in patients who are in remission or uncertain remission
- Identifying the risk of disease relapse or progression
- Guiding decisions about continuing or adjusting maintenance therapy
- Supporting post-transplant surveillance and treatment planning
Myeloma MRD by Flowcytometry Test for Chronic Disease Monitoring
Multiple myeloma is a condition that, while not currently curable, can often be managed over the long term with chemotherapy and personalised treatments. The myeloma MRD by flowcytometry test plays an important role in this ongoing management. Regular MRD monitoring helps doctors assess the depth of treatment response, identify early signs of relapse, and decide whether treatment intensity needs to be changed.
How to Prepare and What to Expect
Preparation is straightforward, but there are a few important things to be aware of before your appointment.
Do You Need to Fast?
No fasting is required for this test. You may eat and drink as normal before your appointment. Always follow specific instructions provided by your doctor.
Practical Tips Before Your Test
Being well prepared helps ensure a smooth experience and accurate results:
- Bring a detailed clinical history including your symptoms, previous test results, and family history, as this is required for the test.
- Inform your doctor about all current medications, especially any anti-CD38 therapies such as daratumumab, as these can affect test results.
- Share information about your current disease state (for example, whether you are untreated, on treatment, or in remission).
- Wear comfortable, loose clothing that allows easy access to the hip area.
- Arrange for someone to accompany you, as the bone marrow aspiration may cause temporary discomfort.
Step-by-Step Procedure
The myeloma MRD by flowcytometry test procedure involves the collection of two sample types: bone marrow aspirate and peripheral blood. Here is what to expect.
Bone Marrow Sample Collection:
- You will be positioned comfortably, and the collection site (usually the hip bone) will be cleaned and prepared.
- A local anaesthetic is applied to reduce discomfort at the collection area.
- A trained specialist inserts a fine needle into the bone marrow and withdraws approximately 3 ml of bone marrow aspirate into a sodium heparin tube and 3 ml into an EDTA tube.
- The tubes are gently inverted immediately after collection to prevent clotting.
Peripheral Blood Sample Collection:
- A trained phlebotomist collects 3 ml of blood from a vein in your arm into a green-top sodium heparin tube using a standard blood draw.
- All samples are labelled, packaged, and transported under refrigeration (2 to 8°C) to the laboratory for flow cytometry analysis.
Factors That Can Affect Accuracy
Certain conditions can influence how reliable the test results are:
- Haemodilution, where blood mixes into and dilutes the bone marrow sample, can reduce accuracy
- Low sample volume or poor cellularity (low cell count) may reduce the sensitivity of the test
- Delays in specimen transport or processing can cause antigen loss and affect results
- Use of anti-CD38 therapies may interfere with the detection of certain plasma cell markers
- Specimen ageing affects the quality of cells available for analysis
Understanding Your Myeloma MRD by Flowcytometry Test Results
Your results will be reported as MRD-negative or MRD-positive. A haematologist or oncologist will interpret the findings alongside your full medical history and other test results. The table below shows key findings:
| Result | Interpretation |
|---|---|
| MRD-Negative | No abnormal plasma cells detected at the test's sensitivity threshold (at least 1 in 100,000 cells). Associated with a deeper treatment response and better outcomes. |
| MRD-Positive | An abnormal plasma cell population was detected. Results include the percentage of abnormal cells among all events analysed. May indicate ongoing disease or higher risk of relapse. |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain situations can influence how results should be read:
- Haemodilution, where blood contaminates the bone marrow sample during collection, can reduce the accuracy of the test and may lead to an underestimate of residual disease.
- Anti-CD38 therapies such as daratumumab interfere with CD38 cell markers, which may affect the detection of abnormal plasma cells.
- Delays in sending the sample to the laboratory or prolonged storage can cause antigen loss, reducing the reliability of findings.
- Low sample cellularity reduces the test's ability to detect small numbers of residual cells.
How to Maintain Healthy Levels
These general tips support overall wellbeing during myeloma management:
- Follow your oncologist's prescribed treatment plan and do not miss scheduled doses or appointments.
- Attend all recommended follow-up consultations and monitoring tests without delay.
- Report any new or worsening symptoms, such as bone pain, unusual fatigue, or frequent infections, to your doctor promptly.
Lupin Diagnostics Myeloma MRD by Flowcytometry Test Price
The myeloma MRD by flowcytometry test cost at Lupin Diagnostics starts at ₹12,000. This test requires a visit to a Lupin Diagnostics centre or an affiliated clinical facility, as home collection is not available. Bone marrow aspiration must be performed by a trained specialist in a clinical or hospital setting. The table below shows indicative prices:
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 12000 |
| CHENNAI | 12000 |
| HYDERABAD | 12000 |
| KOLKATA | 12000 |
| NAVI MUMBAI | 12000 |
| PUNE | 12000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps for myeloma MRD by flowcytometry test online booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection by a trained specialist.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
The myeloma MRD by flowcytometry test is used to detect whether any residual myeloma (cancerous plasma) cells remain in the bone marrow after treatment. It helps doctors confirm whether a patient has achieved remission and guides ongoing treatment decisions.
This test is ordered for patients who have been treated for multiple myeloma and are being assessed for remission or monitored during follow-up. It is not recommended at the time of initial diagnosis or for patients known to be relapsing. Your doctor will advise whether it is appropriate for your situation.
No, myeloma MRD by flowcytometry test home collection is not available. This test requires a bone marrow aspiration, which must be carried out by a qualified specialist in a clinical or hospital setting.
An MRD-negative result means no abnormal plasma cells were detected at the test's sensitivity level. This is associated with a deeper response to treatment and, in general, with longer remissions and better outcomes. Your oncologist will interpret what this means for your specific situation.
At Lupin Diagnostics, the report is typically delivered within 3 days. The test results are delivered directly via email or WhatsApp.
The testing frequency depends on your treatment protocol and your doctor's recommendations. It is commonly used to confirm remission after treatment and for annual follow-up in patients who remain in remission. Your oncologist will advise on the appropriate schedule for your individual situation.
Myeloma MRD by Flowcytometry Test: Booking, Price, and Results
